Australia To Continue AstraZeneca Vaccination Despite Blood Clotting Case

Australia probes if blood clot case linked to AstraZeneca vaccine

But the head of the European Medicines Agency (EMA) has said there is "no evidence" to support restricting the use of the AstraZeneca vaccine in any population.

Despite the cases, the MHRA has said the benefits of the vaccine in preventing COVID-19 outweigh any risks and urged the public to continue coming forward for the jab.

However, he said the risks of taking the AstraZeneca vaccine are still far outweighed by the risks of not getting the jab.

The reports represented 25 more cases than Britain's medicines regulator had previously received, going some way toward addressing a mystery that has hung over safety concerns about the vaccine: why Britain had not observed the same phenomenon that has been seen in continental Europe, driving countries including France, Germany and Sweden to stop giving the shot to younger people, who are believed to be at higher risk from the rare clotting events.

Yesterday, Health director-general Tan Sri Dr Noor Hisham Abdullah said the Drug Control Authority (DCA) has agreed to approve the conditional registration of the Covid-19 Vaccine AstraZeneca Solution for Injection, to be supplied through the Covax facility by South Korean manufacturer SK Bioscience Co Limited, for use during an emergency.

"It is a complaint "against X", because we have no element against a named person for manslaughter", said Boittin, adding that this "classification can evolve" as the case develops.

The European Medicines Agency is expected to update its recommendation on this issue on April 7.

The Netherlands on Friday became the latest in a line of European countries to halt vaccinations with the AstraZeneca jab for people under the age of 60 amid fears of links to rare blood clots.

David Werring, a professor at University College London's Institute of Neurology, said that the unusual presentation of the cases in vaccinated people was creating concern about possible links with the shot.

"Receiving the vaccine is by far the safest choice in terms of minimising individual risk of serious illness or death", he said.

The MHRA said on Thursday there had been "22 reports of cerebral venous sinus thrombosis (CVST) and 8 reports of other thrombosis events with low platelets".

Nevertheless, Australians who have received the vaccine were urged to be vigilant for symptoms.

Figures showed that the United Kingdom has given a first dose of vaccine to 31.4 million people, or around 46 percent of its population, a much higher rate than the rest of Europe.

While investigations continue, both the TGA and the Australian Technical Advisory Group on Immunisation (ATAGI) have said no change to Australia's vaccine rollout was needed. It also ordered 30 million doses of the Pfizer-BioNTech vaccine the same year.

Related:

Comments


Other news